Ignite Creation Date:
2024-05-05 @ 5:03 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00374842
Status:
COMPLETED
Last Update Posted:
2018-06-08
First Post:
2006-09-08
Brief Title:
Study to Evaluate the Immunogenicity and Safety of 2 Formulations of GlaxoSmithKline GSK Biologicals GSK1247446A Low Dose Influenza Vaccine Candidate
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Study to Evaluate the Immunogenicity Safety and Reactogenicity of Adjuvanted Influenza Vaccine Candidates Compared to Fluarix Administered Intramuscularly in Subjects Aged 18-59 Years
Status:
COMPLETED
Status Verified Date:
2016-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the immunogenicity and the safety of candidate vaccines compared to Fluarix administered intramuscularly in subjects aged 18-59 years
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None